Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?

Table 5 Adverse events, compliance and relief of symptoms in the 14d-VA group and the 14d-VAC group, n (%)

Adverse events, compliance and relief of symptoms	Total (n = 367)	14d-VA group (n = 183)	14d-VAC group (n = 184)	P value
Patients with adverse events (yes/no)	39/328 (10.63)	18/165 (9.84)	21/163 (11.41)	0.624
Variety of adverse events
Abdominal discomfort (yes/no)	10/357 (2.72)	3/180 (1.64)	7/177 (3.80)	0.341
Nausea/vomiting (yes/no)	8/359 (2.18)	4/179 (2.19)	4/180 (2.17)	1.000
Bitter taste in mouth (yes/no)	7/360 (1.91)	3/180 (1.64)	4/180 (2.17)	1.000
Diarrhea (yes/no)	7/360 (1.91)	4/179 (2.19)	3/181 (1.63)	0.994
Sour regurgitation/heartburn (yes/no)	5/362 (1.36)	2/181 (1.09)	3/181 (1.63)	1.000
Dry mouth (yes/no)	4/363 (1.09)	2/181 (1.09)	2/182 (1.09)	1.000
Constipation (yes/no)	3/364 (0.82)	1/182 (0.55)	2/182 (1.09)	1.000
Poor appetite (yes/no)	3/364 (0.82)	2/181 (1.09)	1/183 (0.54)	0.996
Dizziness/fatigue (yes/no)	3/364 (0.82)	1/182 (0.55)	2/182 (1.09)	1.000
More saliva (yes/no)	2/365 (0.54)	1/182 (0.55)	1/183 (0.54)	1.000
Others (yes/no)	4/363 (1.09)	1/182 (0.55)	3/181 (1.63)	0.619
Discontinued drugs because of adverse events (yes/no)	3/364 (0.82)	2/181 (1.09)	1/183 (0.54)	0.996
Good compliance (yes/no)	353/14 (96.19)	175/8 (95.63)	178/6 (96.74)	0.579
Relief of symptoms (yes/no)	272/20 (n = 292) (93.15)	129/11 (n = 140) (92.14)	143/9 (n = 152) (94.08)	0.513

P values were obtained from two-sided comparisons of difference between the 14d-VA group and the 14d-VAC group. VA: Vonoprazan-amoxicillin; VAC: Vonoprazan-amoxicillin-clarithromycin.